Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2016 by Dana-Farber Cancer Institute
Miltenyi Biotec GmbH
Prometheus Laboratories
National Cancer Institute (NCI)
Information provided by (Responsible Party):
John Koreth, MD, Dana-Farber Cancer Institute Identifier:
First received: August 30, 2013
Last updated: July 7, 2016
Last verified: July 2016
No Study Results Posted on for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: July 2018
  Estimated Primary Completion Date: November 2016 (Final data collection date for primary outcome measure)